Liang Jieling, Lin Xiaojuan, Liao Xin, Chen Xi, Zhou Ying, Zhang Lin, Qin Yunyun, Meng Haoru, Feng Zhongwen
Department of Pharmacy, Guilin Hospital of the Second Xiangya Hospital, Central South University, Guilin, China.
Department of Pharmacy, Guangxi Academy of Medical Sciences and the People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.
Front Pharmacol. 2025 Jan 23;16:1533984. doi: 10.3389/fphar.2025.1533984. eCollection 2025.
The therapeutic efficacy of Traditional Chinese Medicine (TCM) in modulating gut microbiota for diabetes treatment has garnered increasing scholarly attention. This study aims to meticulously examine current research trajectories and focal areas from 2004 to 2024, providing a foundational framework for future inquiries.
A comprehensive search of documents published between 2004 and 2024 was conducted using the Web of Science database. The resulting data were analyzed and visualized using R software, VOSviewer, and CiteSpace.
The study included a total of 751 documents. From 2004 to 2022, the number of annual publications showed a continuous upward trend (2004: n = 1 to 2022: n = 159), and the number of publications in 2023 (n = 141) decreased slightly from the previous year. China emerged as the leading country in terms of article publications (n = 430). Additionally, the United States played a prominent role in international research collaborations. Frontiers in Pharmacology (n = 31) was the most frequently published journal, while Nature (n = 1,147) achieved the highest citation count. Key identified keywords included obesity, insulin resistance, inflammation, and oxidative stress.
Three key research focuses in this domain include: the therapeutic effects of active constituents in TCM on diabetes via gut microbiota modulation, the underlying mechanisms through which TCM influences gut microbiota in diabetes management, and the targeted regulation of specific gut bacterial populations by TCM in the treatment of diabetes.
中医药在调节肠道微生物群以治疗糖尿病方面的治疗效果已获得越来越多的学术关注。本研究旨在细致考察2004年至2024年期间当前的研究轨迹和重点领域,为未来的研究提供一个基础框架。
使用科学网数据库对2004年至2024年期间发表的文献进行全面检索。使用R软件、VOSviewer和CiteSpace对所得数据进行分析和可视化。
该研究共纳入751篇文献。从2004年到2022年,年发表量呈持续上升趋势(2004年:n = 1至2022年:n = 159),2023年的发表量(n = 141)较上一年略有下降。中国在论文发表数量方面位居首位(n = 430)。此外,美国在国际研究合作中发挥了重要作用。《药理学前沿》(n = 31)是发表频率最高的期刊,而《自然》(n = 1147)的被引次数最高。确定的关键关键词包括肥胖、胰岛素抵抗、炎症和氧化应激。
该领域的三个关键研究重点包括:中药活性成分通过调节肠道微生物群对糖尿病的治疗作用;中药在糖尿病管理中影响肠道微生物群的潜在机制;中药在糖尿病治疗中对特定肠道细菌种群的靶向调节。